September 27, 2023 11:16 AM EDT

Théa won't buy ProQR's ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

ProQR’s failed divestiture: Laboratoires Théa scrapped plans to buy ProQR Therapeutics’ late-stage ophthalmic pipeline after announcing a deal in early …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Théa won't buy ProQR's ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October

Jaimy Lee

Deputy Editor

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Pfizer partners with two more Flagship biotechs on obesity, cancer

When generative AI meets the FDA: First digital health adcomm kicks off discussion

Are programs with compounded GLP-1s safe for your population?

Théa won't buy Pro­QR's oph­thalmic as­sets; Im­muno­vant’s $130M of­fer­ing; In­ozyme to start piv­otal study in Oc­to­ber

Deputy Editor

Senior Reporter

News Reporter

Sign up to read this article for free.

Théa won't buy ProQR's ophthalmic assets; Immunovant’s $130M offering; Inozyme to start pivotal study in October